Nanobiotix announced positive Phase 1 data for NBTXR3 (JNJ-1900), a radiotherapy-activated nanoparticle therapy, in patients with locally advanced non-small cell lung cancer (NSCLC) who had undergone prior treatment. The study, sponsored by MD Anderson Cancer Center, showed a favorable safety profile and promising efficacy signals. Specifically, the dose escalation part found no dose-limiting toxicities, and early survival data indicated a 12-month local progression-free survival rate of 64% and a 12-month overall survival rate of 83%.
These results are particularly important for NSCLC patients who experience locoregional recurrence after initial chemoradiation, as they often have limited treatment options. The fact that NBTXR3 was shown to be safe and potentially effective in this difficult-to-treat population, even at lower radiation doses than prior therapies, signifies a meaningful advancement. Current re-irradiation strategies often necessitate lower, palliative doses due to toxicity concerns, limiting their potential to control disease progression. NBTXR3’s ability to enhance the effects of radiation without exacerbating toxicity could lead to significantly improved outcomes for these patients.
The completed dose escalation part of the trial confirmed injection feasibility and established the recommended Phase 2 dose. Preliminary data from 12 patients demonstrated the encouraging survival rates mentioned earlier. The expansion phase of the study, currently enrolling patients, will provide further data to solidify these initial observations. Five out of the planned 12 patients in this phase have been injected with NBTXR3 to date.
This positive early data for NBTXR3 suggests a potential new therapeutic avenue for patients with recurrent NSCLC who have exhausted other treatment options. If the expansion phase continues to yield positive results, NBTXR3 could become a crucial component of treatment regimens for this patient population, offering the possibility of improved survival and quality of life. This also has broader implications for the field of radiation oncology, potentially opening the door for new approaches using nanoparticle-enhanced radiotherapy for other cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
